{"product_id":"passagebio-marketing-mix","title":"Passage Bio Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Passage Bio’s product development, pricing structure, distribution channels, and promotional tactics align to target rare-disease markets—download the full 4Ps Marketing Mix Analysis for an editable, presentation-ready report that saves hours of research and delivers actionable insights for strategy, benchmarking, or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBFT02 Gene Therapy for FTD-GRN\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s product strategy centers on PBFT02, a lead AAV-mediated gene therapy for frontotemporal dementia caused by GRN mutations, aiming to restore progranulin (PGRN) in the CNS.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 PBFT02 reached late Phase 1\/early Phase 2 milestones with multiple-dose data showing target-engagement (CSF PGRN up ~2–4x in interim cohorts) and no dose-limiting safety signals.\u003c\/p\u003e\n\u003cp\u003eThe therapy targets a clear unmet need: FTD-GRN has median survival ~6–8 years and no approved disease-modifying treatments, addressing a genetically defined, rapidly progressive population.\u003c\/p\u003e\n\u003cp\u003eBusiness-wise, Passage Bio guided 2025 R\u0026amp;D spend near $120M and positions PBFT02 as a near-term value driver ahead of pivotal trials and potential licensing or partner deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary AAVhu68 Delivery Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Proprietary AAVhu68 Delivery Platform centers on the AAVhu68 capsid, licensed from the University of Pennsylvania, engineered to boost CNS (brain and spinal cord) biodistribution while reducing immune activation.\u003c\/p\u003e\n\u003cp\u003ePreclinical and early clinical data through 2025 show improved transduction versus AAV9 in spinal cord and cortical targets, with anti-AAV neutralizing antibody rates under 20% in screened populations.\u003c\/p\u003e\n\u003cp\u003ePassage Bio positions AAVhu68 as its foundational tech across programs, supporting pipeline valuation and de-risking; R\u0026amp;D spend linked to capsid development was about $120–140M in 2024–25.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBGM01 for GM1 Gangliosidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s PBGM01 is a cisterna magna–delivered AAV gene therapy for pediatric GM1 gangliosidosis, aiming to halt neurodegeneration in infants and children; GM1 affects ~1 in 100,000–200,000 births. \u003c\/p\u003e\n\u003cp\u003eBy late 2025 PBGM01 anchors the pediatric rare-disease push and portfolio diversification; Passage Bio reported R\u0026amp;D spend of $78.2M in 2024 and lists PBGM01 as a lead clinical candidate. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision CNS Injection Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision CNS Injection Technology uses intra-cisterna magna (ICM) delivery to bypass the blood-brain barrier, placing gene therapy directly into cerebrospinal fluid for higher CNS exposure and lower systemic dose.\u003c\/p\u003e\n\u003cp\u003ePassage Bio supplies standardized ICM protocols and on-site technical training; in 2025 their SOPs and training reduced administration variability by ~30% in trials, improving dosing accuracy and safety monitoring.\u003c\/p\u003e\n\u003cp\u003eThis procedural component is critical: accurate CSF delivery correlates with efficacy signals in early studies and reduces off-target risks for neurodegenerative indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect CSF delivery via ICM\u003c\/li\u003e\n\u003cli\u003eCompany-supplied SOPs and training\u003c\/li\u003e\n\u003cli\u003e~30% reduction in admin variability (2025 trial data)\u003c\/li\u003e\n\u003cli\u003eImproved CNS exposure, lower systemic dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline of Preclinical CNS Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBeyond lead clinical assets, Passage Bio’s product mix includes multiple preclinical CNS programs targeting high-genetic-certainty disorders like GM2, CDKL5 deficiency, and Friedreich ataxia, expanding pipeline depth.\u003c\/p\u003e\n\u003cp\u003eThese programs reuse the company’s AAV (adeno-associated virus) platform to standardize vector design, reducing per-program development time and cost and creating a repeatable rare-disease model.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, these assets could drive long-term value and partner interest; Passage Bio held ~20 programs across discovery\/preclinical as of 2024 and seeks collaborations to de-risk development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical CNS focus: GM2, CDKL5, Friedreich ataxia\u003c\/li\u003e\n\u003cli\u003eShared AAV platform: lower marginal cost, faster iteration\u003c\/li\u003e\n\u003cli\u003ePipeline scale: ~20 discovery\/preclinical programs (2024)\u003c\/li\u003e\n\u003cli\u003eValue driver: partnership\/licensing potential by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio advances AAVhu68-led gene therapies: PBFT02 gains traction, PBGM01 in clinic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s product mix centers on PBFT02 (AAVhu68 CNS gene therapy for FTD-GRN) and PBGM01 (ICM AAV for GM1), backed by AAVhu68 platform, ICM delivery SOPs, ~20 preclinical programs, and 2024–25 R\u0026amp;D spend ~ $120–140M (capsid) + $78.2M (PBGM01-related 2024). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBFT02\u003c\/td\u003e\n\u003ctd\u003eFTD-GRN\u003c\/td\u003e\n\u003ctd\u003elate Ph1\/early Ph2\u003c\/td\u003e\n\u003ctd\u003eCSF PGRN ↑2–4x; no DLTs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGM01\u003c\/td\u003e\n\u003ctd\u003eGM1\u003c\/td\u003e\n\u003ctd\u003eclinical\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D $78.2M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAVhu68\u003c\/td\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003elicensed\u003c\/td\u003e\n\u003ctd\u003eanti-AAV NAb \u0026lt;20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICM tech\u003c\/td\u003e\n\u003ctd\u003eDelivery\u003c\/td\u003e\n\u003ctd\u003eSOPs\/training\u003c\/td\u003e\n\u003ctd\u003eadmin variability −30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Passage Bio’s Product, Price, Place, and Promotion strategies, using real operational context and competitive positioning to inform strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Passage Bio's 4P marketing strategy into a concise, leadership-ready snapshot that simplifies positioning, pricing, promotion, and product decisions for quick alignment and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Academic Research Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio distributes clinical-stage AAV gene therapies via a network of \u0026gt;25 leading academic medical centers and specialized hospitals selected for neurology expertise and safe intracebral\/intracisternal (ICM) injection capability.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the network spans key regions—North America and Europe—supporting enrollment for 4 active trials and \u0026gt;350 screened patients to date.\u003c\/p\u003e\n\u003cp\u003eThese centers reduce site activation time to ~90 days and cut per-patient administration cost variance, improving trial throughput and potential commercial readiness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Hub at UPenn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Collaborative Research Hub at UPenn anchors Passage Bio’s place strategy through its deep tie to the University of Pennsylvania Gene Therapy Program, giving access to GMP-like labs and vector manufacturing know-how that are costly to replicate; UPenn’s Gene Therapy Program handled over 300 IND-enabling projects and supported 40+ clinical gene therapy trials through 2024, speeding candidate moves from discovery to file-ready status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Cold Chain Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio relies on specialized cold chain logistics—ultra-low temperature storage and cryogenic transport—to move AAV gene therapies from GMP sites to clinics, using providers certified for \u0026lt;-70°C handling; in 2025 their logistics spend rose ~18% year-over-year to support temperature-controlled shipments. Maintaining transit integrity is central: real-time temperature monitoring and chain-of-custody tracking cut spoilage risk, keeping product potency for on-site dosing and regulatory compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Clinical Trial Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio uses digital clinical trial portals to centralize data flow between sites, investigators, and HQ, enabling real-time safety monitoring and outcome collection across global programs.\u003c\/p\u003e\n\u003cp\u003eThese portals supported Passage Bio’s 2025 enrollment drives, cutting data query turnaround by ~40% and helping maintain 21 CFR Part 11 compliance for regulatory submissions.\u003c\/p\u003e\n\u003cp\u003ePortals reduce monitoring travel spend and speed database lock—improving trial efficiency and oversight for rare-disease gene therapy programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized data sharing—real-time access for sites and HQ\u003c\/li\u003e\n\u003cli\u003eSafety monitoring—continuous adverse event tracking\u003c\/li\u003e\n\u003cli\u003eRegulatory-ready—supports 21 CFR Part 11 audits\u003c\/li\u003e\n\u003cli\u003eEfficiency—~40% faster query resolution (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Market Access Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio’s place strategy centers on FDA and EMA regulatory pathways, targeting orphan drug and fast-track designations to shorten approvals and market entry by late 2025; orphan status can add up to 7 years exclusivity in the U.S. and 10 in the EU.\u003c\/p\u003e\n\u003cp\u003eThese designations shape which jurisdictions can legally receive its gene therapies and influence reimbursement discussions and launch sequencing tied to clinical and regulatory milestones.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: orphan + fast-track by late 2025\u003c\/li\u003e\n\u003cli\u003eU.S. exclusivity: up to 7 years; EU: up to 10 years\u003c\/li\u003e\n\u003cli\u003eRegulatory success drives launch markets and payer negotiations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio: 25+ specialized sites, 4 trials, 350+ screens, 90‑day activation, 40% faster queries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s place strategy leverages \u0026gt;25 specialized centers (North America, Europe) supporting 4 active trials and \u0026gt;350 screened patients (2025), ~90-day site activation, UPenn hub (300+ IND projects, 40+ trials through 2024), cold-chain spend +18% YoY (2025), portals cut query time ~40% and support 21 CFR Part 11; targeted orphan\/fast-track designations (U.S. exclusivity up to 7 years; EU up to 10 years).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003e4 active\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients screened\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;350\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite activation\u003c\/td\u003e\n\u003ctd\u003e~90 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain spend YoY\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuery time improvement\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePassage Bio 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Passage Bio 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751171371385,"sku":"passagebio-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/passagebio-marketing-mix.png?v=1772228563","url":"https:\/\/matrixbcg.com\/products\/passagebio-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}